Literature DB >> 10706557

Fas- and tumor necrosis factor receptor 1-dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice.

Z X Liu1, S Govindarajan, S Okamoto, G Dennert.   

Abstract

Intravenous injection of type 5 adenovirus, deleted in the E1 and E3 regions, is shown to result in expression of viral antigens in the liver, initiating lymphocyte infiltration and liver injury. Following this infection, induction of Fas ligand (FasL), tumor necrosis factor alpha (TNF-alpha), and perforin mRNA are all demonstrable in the liver, pointing to a role of respective pathways in liver injury. Making use of mice in which the genes coding for Fas, FasL, TNF receptors (TNFRs), and perforin are inactivated, as well as recombinant proteins that inhibit Fas- and TNF-alpha-mediated apoptosis, it is shown that a functional perforin-mediated mechanism is not obligatory for cellular infiltration and progression of liver injury. In contrast functional Fas- and TNF-alpha-mediated mechanisms were found to be essential for liver injury to occur. Results are presented demonstrating that signaling through TNFR1, but not TNFR2, is involved in TNF-alpha-mediated liver damage. The conclusion is drawn that although perforin mRNA is induced in the virus-infected liver, Fas- and TNF-alpha-mediated mechanisms constitute the principal pathways by which the cell-mediated immune system causes acute liver injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706557     DOI: 10.1002/hep.510310317

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  Increased sensitivity to staphylococcal enterotoxin B following adenoviral infection.

Authors:  Timur O Yarovinsky; Michael P Mohning; Mary A Bradford; Martha M Monick; Gary W Hunninghake
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

2.  Hepatitis C virus genotype 1b core protein does not exert immunomodulatory effects on virus-induced cellular immunity.

Authors:  Zhang-Xu Liu; Hiroshi Nishida; Jian-Wen He; Michael M C Lai; Ni Feng; Gunther Dennert
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

3.  Indirect action of tumor necrosis factor-alpha in liver injury during the CD8+ T cell response to an adeno-associated virus vector in mice.

Authors:  Matthew Giannandrea; Robert H Pierce; Ian Nicholas Crispe
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

4.  GammadeltaT cells initiate acute inflammation and injury in adenovirus-infected liver via cytokine-chemokine cross talk.

Authors:  Maureen N Ajuebor; Yijun Jin; Griffin L Gremillion; Robert M Strieter; Qingling Chen; Patrick A Adegboyega
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

5.  The role of serpinb9/serine protease inhibitor 6 in preventing granzyme B-dependent hepatotoxicity.

Authors:  Heather W Stout-Delgado; Yonas Getachew; Thomas E Rogers; Bonnie C Miller; Dwain L Thiele
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

6.  IL-33 induces nuocytes and modulates liver injury in viral hepatitis.

Authors:  Yuejin Liang; Zuliang Jie; Lifei Hou; Renan Aguilar-Valenzuela; David Vu; Lynn Soong; Jiaren Sun
Journal:  J Immunol       Date:  2013-04-29       Impact factor: 5.422

Review 7.  Novel Immunotherapies for Autoimmune Hepatitis.

Authors:  Shamir Cassim; Marc Bilodeau; Catherine Vincent; Pascal Lapierre
Journal:  Front Pediatr       Date:  2017-01-26       Impact factor: 3.418

Review 8.  Immunopathobiology and therapeutic targets related to cytokines in liver diseases.

Authors:  Yong He; Seonghwan Hwang; Yeni Ait Ahmed; Dechun Feng; Na Li; Marcelle Ribeiro; Fouad Lafdil; Tatiana Kisseleva; Gyongyi Szabo; Bin Gao
Journal:  Cell Mol Immunol       Date:  2020-11-17       Impact factor: 11.530

Review 9.  Ambiguous roles of innate lymphoid cells in chronic development of liver diseases.

Authors:  Yue Shen; Jing Li; Si-Qi Wang; Wei Jiang
Journal:  World J Gastroenterol       Date:  2018-05-14       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.